Latoya Howard
Nurse Practitioner · Natchitoches, LANPI 1649843160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,198 and has fallen 73.6% since, to $316 in 2025.
Across 154 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$617
- Daiichi Sankyo Inc.$377
- Incyte Corporation$279
- Merck$253
- Bristol Myers Squibb$251
- Astellas Pharma US Inc$161
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,86895%
- Education$1665%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $617 |
| Daiichi Sankyo Inc. | 14 | $377 |
| Incyte Corporation | 17 | $279 |
| Merck | 12 | $253 |
| Bristol Myers Squibb | 14 | $251 |
| Astellas Pharma US Inc | 6 | $161 |
| Genentech USA, Inc. | 8 | $147 |
| AstraZeneca(2 entities) | 7 | $123 |
| Jazz Pharmaceuticals Inc. | 5 | $121 |
| Pfizer | 7 | $119 |
| Sanofi | 4 | $94 |
| Beigene USA, Inc. | 5 | $88 |
| Pharmaessentia USA Corporation | 3 | $73 |
| Seagen Inc. | 3 | $45 |
| Karyopharm Therapeutics Inc. | 2 | $37 |
| EMD Serono, Inc. | 2 | $32 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Amgen | 1 | $14 |
| Genmab U.S., Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$3,034 in reported general payments places this provider in the 85th percentile of 969 nurse practitioner providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 13 | $162 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Natchitoches
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
- Amanda EstapaHammond$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.